Abstract
Use of low dose epoetin alfa in the critically ill does not reduce the number of patients requiring blood transfusion, or units of red blood cells transfused. There may be a mortality benefit in trauma patients. Epoetin alfa is associated with an increased risk of thrombotic events.
Level of evidence: 1++ (RCT with a very low risk of bias)